Managing Synthetic Cannabinoid Toxicity and Withdrawal: What Clinicians Know So Far
A review found that daily synthetic cannabinoid use produces dependence and withdrawal that is poorly characterized, with limited evidence suggesting benzodiazepines and quetiapine may provide some symptom relief.
Quick Facts
What This Study Found
This review addressed both acute toxicity and the less-discussed problem of dependence and withdrawal from synthetic cannabinoids (SCs).
While case reports and media coverage focus on severe acute toxicity, the review highlighted that daily SC use resulting in dependence and withdrawal is a significant and often overlooked concern. Data collected from cannabis smokers in New York City over 3.5 years (2012-2015) confirmed a subset of people who use SCs daily.
There is no established evidence-based treatment for SC withdrawal. Some symptom relief has been reported with benzodiazepines and the atypical antipsychotic quetiapine, but controlled studies are lacking. The review called urgently for empirical studies on SC acute effects, withdrawal characterization, and treatment strategies.
Key Numbers
3.5 years of survey data (2012-2015) from the NYC metropolitan area. Benzodiazepines and quetiapine showed some withdrawal symptom relief. No controlled treatment studies existed at the time.
How They Did This
Literature review combined with original survey data on SC use demographics, frequency, and adverse effects from the New York City metropolitan area (2012-2015).
Why This Research Matters
As synthetic cannabinoids continue to circulate, clinicians need guidance on managing not just acute crises but also the dependence and withdrawal that develop with regular use. The current lack of evidence-based treatment protocols leaves clinicians without clear direction.
The Bigger Picture
While much attention focuses on the dramatic acute toxicity of synthetic cannabinoids, the chronic use and dependence aspect may affect more people over time. The review highlighted a gap in addiction medicine: extensive treatment literature exists for most substances of abuse, but almost nothing for synthetic cannabinoids.
What This Study Doesn't Tell Us
The review acknowledged a lack of controlled studies on SC effects and treatment. Survey data from NYC may not represent other regions. The rapidly changing SC market means findings about specific compounds may become outdated quickly.
Questions This Raises
- ?What is the typical timeline and severity of SC withdrawal?
- ?Would treatments effective for cannabis withdrawal also work for SC withdrawal?
Trust & Context
- Key Stat:
- No established evidence-based treatment exists for synthetic cannabinoid withdrawal
- Evidence Grade:
- This review combines published literature with original survey data but notes the near-complete absence of controlled treatment studies.
- Study Age:
- Published in 2016. Some additional clinical experience with SC withdrawal has accumulated since then.
- Original Title:
- Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.
- Published In:
- Current psychiatry reports, 18(5), 52 (2016)
- Authors:
- Cooper, Ziva D(28)
- Database ID:
- RTHC-01131
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is synthetic cannabinoid withdrawal dangerous?
SC withdrawal can be significant and distressing, though it has not been as systematically characterized as withdrawal from other substances. Symptoms may include anxiety, insomnia, irritability, and in some cases more severe neurological effects. The lack of controlled studies means the full risk profile is not well understood.
Why is SC dependence harder to treat than cannabis dependence?
SCs are full agonists at CB1 receptors (more potent than THC), the compounds vary unpredictably between batches, and there are no standardized treatment protocols. Additionally, SC users often have more complex substance use patterns and psychiatric comorbidities.
Read More on RethinkTHC
- 30-days-without-weed
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- THC-purity-potency-label-meaning
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- creativity-without-weed-quitting-artist-musician
- dab-concentrate-addiction-withdrawal
- delta-8-addiction-withdrawal
- edible-addiction-withdrawal-different
- edibles-psychosis-emergency-room
- healthiest-way-to-consume-cannabis
- hobbies-after-quitting-weed
- how-cannabis-products-made-concentrates-edibles
- identity-after-quitting-weed
- laced-weed-fentanyl-contaminated-vape
- leaving-stoner-culture-identity
- legal-weed-vs-street-weed-quality-safety
- money-saved-quitting-weed-calculator
- one-year-sober-weed
- quitting-dabs-withdrawal
- quitting-edibles-withdrawal
- quitting-weed-creativity
- quitting-weed-face-changes-skin
- quitting-weed-weight-loss-gain
- sativa-vs-indica-difference-myth
- weed-potency-withdrawal
Cite This Study
https://rethinkthc.com/research/RTHC-01131APA
Cooper, Ziva D. (2016). Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.. Current psychiatry reports, 18(5), 52. https://doi.org/10.1007/s11920-016-0694-1
MLA
Cooper, Ziva D. "Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.." Current psychiatry reports, 2016. https://doi.org/10.1007/s11920-016-0694-1
RethinkTHC
RethinkTHC Research Database. "Adverse Effects of Synthetic Cannabinoids: Management of Acu..." RTHC-01131. Retrieved from https://rethinkthc.com/research/cooper-2016-adverse-effects-of-synthetic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.